Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine
Sponsors
National Institute For Infectious Diseases Lazzaro Spallanzani, Finnish Institute For Health And Welfare
Conditions
COVID-19 infectionCovid-19 infection
Phase 4
Temporal kinetics of antibody and cellular response markers and relative impact of
revaccination in patients recovered from COVID-19 after treatment with monoclonal
antibodies
Not yet recruitingCTIS2024-514071-17-00
Target: 150Updated: 2025-01-14
COVID-19 vaccine immunological studies in Finland
CompletedCTIS2024-517357-27-00
Start: 2021-12-07End: 2025-12-17Target: 4000Updated: 2025-02-05